Previous 10 | Next 10 |
Gainers: Scholar Rock (SRRK) +26%. Phathom Pharmaceuticals (PHAT) +12%. 4d Pharma (LBPS) +10%. Ocular Therapeutix (OCUL) +9%. Magenta Therapeutics (MGTA) +8%. Losers: PolarityTE (PTE) -34%. Tonix Pharmaceuticals (TNXP) -22%. Albireo Pharma (ALBO) ...
4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the presentation of a late-breaking poster on data from Part A of the Phase I/II tria...
Checkmate Pharmaceuticals (CMPI) +332% Regeneron to acquire Checkmate Pharma in $250 million all-cash deal. Axsome Therapeutics (AXSM) +27%. Super Micro Computer (SMCI) +16% on raised Q3 guidance. 4D pharma (LBPS) +13%. American Campus Communities (ACC) +13% Blac...
Antares Pharma ATRS +49% on ~$1B acquisition deal by Halozyme. Sierra Oncology SRRA +37% GSK to acquire Sierra Oncology for $1.9B to bolster specialty meds. BriaCell Therapeutics (BCTX) +17% receives FDA fast track approval for targeted breast cancer immunotherapy. Hi...
Veru (VERU) +31% after interim results for COVID-19 therapy. SailPoint Technologies (SAIL) +30% acquisition could lead to other cyber security deals, Wedbush says. Iveda Solutions (IVDA) +28%. VNET Group (VNET) +20% receives buyout offer of $1.3333 per share. Aff...
Gainers: ORIC Pharmaceuticals (ORIC) +14%. Unity Biotechnology (UBX) +13%. Applied Therapeutics (APLT) +11%. Genetron (GTH) +11%. Clarus Therapeutics (CRXT) +8%. Losers: SELLAS Life Sciences SLS -39%. Pulse Biosciences (PLSE) -22%. Spero Therapeutics SPRO...
4d Pharma claims to be a world leader in the development of live biotherapeutics. Positive interim results were announced last week from the trial of lead combo therapy candidate. Form F-3 has been filed with the SEC to raise up to $150 million. For further details see: ...
4D pharma press release (NASDAQ:LBPS): FY Loss and total comprehensive income for the full year 2021 was $32.1 million. Cash and cash equivalents of $21.0 million as of December 31, 2021. For further details see: 4D pharma reports FY results
4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial results for the full year ending December 31, 2021 and highlighted its key c...
Guardforce AI (GFAI) +46% is expanding it footprint by establishing subsidiaries in Dubai and Australia. IGM Biosciences (IGMS) +32% on proposed stock offering. Hycroft Mining Holding (HYMC) +23% GameStop, AMC and Bed Bath pull off a meme stock comeback. Nielsen Holdi...
News, Short Squeeze, Breakout and More Instantly...
4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC (ȁ...
4D pharma plc (AIM: DDDD, Nasdaq: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to the announcement released earlier today regarding the Company’s request for a...
- Study to assess safety of MRx0518 with BAVENCIO and effect on progression-free survival at 6 months - Study sites are open for patient enrolment 4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LB...